Franklin Street Advisors’s Epizyme, Inc EPZM Stock Holding History

Franklin Street Advisors’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-23,050	Closed	-$625K	–	229
2014 Q3	$625K	Sell	23,050 -5,050	-18%	-$157K	0.12%	147
2014 Q2	$874K	Sell	28,100 -200	-0.7%	-$4.71K	0.17%	126
2014 Q1	$644K	Buy	28,300 +200	+0.7%	+$6.06K	0.13%	153
2013 Q4	$584K	Buy	28,100 +7,050	+33%	+$204K	0.12%	154
2013 Q3	$842K	Sell	21,050 -2,500	-11%	-$84.7K	0.19%	129
2013 Q2	$662K	Buy	+23,550	New	+$605K	0.16%	150

Other funds holding EPZM

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

Franklin Street Advisors's EPZM Position: Q4 2014 in Review

Franklin Street Advisors sold out of Epizyme, Inc (EPZM) in Q4 2014, closing a stake of 23,050 shares — an estimated $625K sold.

Franklin Street Advisors first reported a position in EPZM in Q2 2013 and held it in 6 quarters. The position peaked at $874K in Q2 2014. 82 funds tracked by Wall St. Rank hold EPZM as of Q4 2014.

Franklin Street Advisors reported no remaining Epizyme, Inc position as of Q4 2014 after selling out during the quarter.
Franklin Street Advisors sold 23,050 Epizyme, Inc shares in Q4 2014, an estimated $625K.
Franklin Street Advisors first reported a position in Epizyme, Inc in Q2 2013 and held it in 6 quarters.
Franklin Street Advisors's Epizyme, Inc position peaked at $874K in Q2 2014.
82 funds tracked by Wall St. Rank held Epizyme, Inc as of Q4 2014.

Based on Franklin Street Advisors's 13F filing for Q4 2014, filed 9 Jan 2015.